BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 10447957)

  • 1. Carboxylic acid analogues of tamoxifen: (Z)-2-[p-(1, 2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine. Estrogen receptor affinity and estrogen antagonist effects in MCF-7 cells.
    Kraft KS; Ruenitz PC; Bartlett MG
    J Med Chem; 1999 Aug; 42(16):3126-33. PubMed ID: 10447957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogenic triarylethylene acetic acids: effect of structural variation on estrogen receptor affinity and estrogenic potency and efficacy in MCF-7 cells.
    Ruenitz PC; Bourne CS; Sullivan KJ; Moore SA
    J Med Chem; 1996 Nov; 39(24):4853-9. PubMed ID: 8941399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
    Murphy CS; Parker CJ; McCague R; Jordan VC
    Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
    Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF
    Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guide-lines in the design of new antiestrogens and cytotoxic-linked estrogens for the treatment of breast cancer.
    Leclercq G; Devleeschouwer N; Heuson JC
    J Steroid Biochem; 1983 Jul; 19(1A):75-85. PubMed ID: 6887875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of basic side chain derivatives of Analog II as pure antiestrogens and antitumor agents.
    Magarian RA; Avor KS; Overacre LB; Kunchandy J; Paxton TR
    Anticancer Drug Des; 1995 Jun; 10(4):311-31. PubMed ID: 7786397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of antagonistic activity of tamoxifen by replacement of one N-methyl of its side chain by fluorinated residues.
    Agouridas V; Laïos I; Cleeren A; Kizilian E; Magnier E; Blazejewski JC; Leclercq G
    Bioorg Med Chem; 2006 Nov; 14(22):7531-8. PubMed ID: 16870452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and structure-activity relationships of ferrocenyl tamoxifen derivatives with modified side chains.
    Nguyen A; Top S; Pigeon P; Vessières A; Hillard EA; Plamont MA; Huché M; Rigamonti C; Jaouen G
    Chemistry; 2009; 15(3):684-96. PubMed ID: 19053086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.
    Palkowitz AD; Glasebrook AL; Thrasher KJ; Hauser KL; Short LL; Phillips DL; Muehl BS; Sato M; Shetler PK; Cullinan GJ; Pell TR; Bryant HU
    J Med Chem; 1997 May; 40(10):1407-16. PubMed ID: 9154963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiestrogens. 3. Estrogen receptor affinities and antiproliferative effects in MCF-7 cells of phenolic analogues of trioxifene, [3,4-dihydro-2-(4- methoxyphenyl)-1-naphthalenyl][4-[2-(1-pyrrolidinyl)ethoxy]- phenyl]methanone.
    Jones CD; Blaszczak LC; Goettel ME; Suarez T; Crowell TA; Mabry TE; Ruenitz PC; Srivatsan V
    J Med Chem; 1992 Mar; 35(5):931-8. PubMed ID: 1548683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Status of estrogen receptor affects the drug sensitivity of drug-resistant MCF-7/Adr human breast cancer cells to droloxifene and Adriamycin].
    Gao HD; Sun JZ; Bi DS; Ma R
    Ai Zheng; 2003 Apr; 22(4):376-9. PubMed ID: 12703992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiestrogenic activity of DP-TAT-59, an active metabolite of TAT-59 against human breast cancer.
    Toko T; Shibata J; Nukatsuka M; Yamada Y
    Cancer Chemother Pharmacol; 1997; 39(5):390-8. PubMed ID: 9054952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines.
    Top S; Vessières A; Leclercq G; Quivy J; Tang J; Vaissermann J; Huché M; Jaouen G
    Chemistry; 2003 Nov; 9(21):5223-36. PubMed ID: 14613131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histamine and growth: interaction of antiestrogen binding site ligands with a novel histamine site that may be associated with calcium channels.
    Brandes LJ; Bogdanovic RP; Cawker MD; LaBella FS
    Cancer Res; 1987 Aug; 47(15):4025-31. PubMed ID: 2886214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modification of the basic side chain in tamoxifen: effects on microsomal metabolism and in vitro biological activity.
    Foster AB; McCague R; Seago A; Leclercq G; Stoessel S; Roy F
    Anticancer Drug Des; 1986 Nov; 1(3):245-57. PubMed ID: 3450297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homologs of idoxifene: variation of estrogen receptor binding and calmodulin antagonism with chain length.
    Hardcastle IR; Rowlands MG; Grimshaw RM; Houghton J; Jarman M
    J Med Chem; 1996 Feb; 39(4):999-1004. PubMed ID: 8632423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells.
    Swami S; Krishnan AV; Feldman D
    Clin Cancer Res; 2000 Aug; 6(8):3371-9. PubMed ID: 10955825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells.
    Liu ZJ; Zhu BT
    J Steroid Biochem Mol Biol; 2004 Mar; 88(3):265-75. PubMed ID: 15120420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flexible estrogen receptor modulators: design, synthesis, and antagonistic effects in human MCF-7 breast cancer cells.
    Meegan MJ; Hughes RB; Lloyd DG; Williams DC; Zisterer DM
    J Med Chem; 2001 Mar; 44(7):1072-84. PubMed ID: 11297454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural requirements for the pharmacological activity of nonsteroidal antiestrogens in vitro.
    Jordan VC; Lieberman ME; Cormier E; Koch R; Bagley JR; Ruenitz PC
    Mol Pharmacol; 1984 Sep; 26(2):272-8. PubMed ID: 6482874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.